Antithrombotic therapy after transcatheter aortic valve replacement

Paul Guedeney, Roxana Mehran, Jean Philippe Collet, Bimmer E. Claessen, Jurriën Ten Berg, George D. Dangas

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


The performance of transcatheter aortic valve replacement has expanded considerably during the past decade. Technological advances and refinement in implantation techniques have resulted in improved procedural outcomes, whereas indications are progressively extending toward lower-risk patients. Ischemic/embolic complications and major bleeding remain important and strongly correlate to mortality. In this regard, the optimal antithrombotic regimen after successful transcatheter aortic valve replacement remains unclear, in the absence of randomized trials. For patients without an indication for oral anticoagulation, empirical treatment with dual antiplatelet therapy (aspirin plus clopidogrel) for 3 to 6 months is currently recommended. However, dual antiplatelet therapy has been preliminarily associated with increased risk of bleeding compared with single antiplatelet therapy without significant ischemic benefit. Non-vitamin K oral anticoagulants and warfarin have also entered clinical investigation, to address the issue of preexisting or new-onset of atrial fibrillation and potentially attenuate subclinical leaflet thrombosis. Clinical trials are necessary to systematically address the risks and benefits of these approaches. In this review, we present the pathophysiological mechanisms of post-transcatheter aortic valve replacement complications and provide updated insights on the rationale behind the various antithrombotic regimens being currently evaluated in large randomized trials.

Original languageEnglish
Article numbere007411
JournalCirculation: Cardiovascular Interventions
Issue number1
StatePublished - 2019


  • Anticoagulant
  • Aspirin
  • Clopidogrel
  • Stroke
  • Transcatheter aortic valve replacement


Dive into the research topics of 'Antithrombotic therapy after transcatheter aortic valve replacement'. Together they form a unique fingerprint.

Cite this